AbCellera Joins the CATALIS Network
CATALIS is delighted to welcome AbCellera to its Network of Partners. This new pharmaceutical company will strengthen the CATALIS Network by joining the other partners: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb (BMS), GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. Together, these partners support CATALIS in its mission to optimize the clinical research environment in Quebec in order to accelerate the development of innovative care for the benefit of patients across the province.
“The AbCellera team is thrilled to join the CATALIS Network as we continue to build our capacity to discover, develop, and manufacture new drugs in Canada. By conducting clinical research using local networks, we can forge a path for Canadian patients to be among the first in the world to benefit from innovative treatment options being developed. We look forward to working with members of the CATALIS Network to make the drugs patients need available faster.” – Véronique Lecault, Director and Chief of Operations, AbCellera
